Cormorant Asset Management, LP Q1 2021 Filing

Filed May 17, 2021

Portfolio Value

$4.5B

Holdings

119

Report Date

Q1 2021

Filing Type

13F-HR

All Holdings (119 positions)

#	Stock	Shares	Value	% Portfolio	Type
101	CLDNEUREIGER BIOPHARMACEUTICALS INC	400,000	$3.5M	0.08%
102	—KADMON HLDGS INC	750,000	$2.9M	0.07%
103	ALLKGUSDALLAKOS INC	25,000	$2.9M	0.06%
104	NUVBNUVATION BIO INC	234,445	$2.5M	0.05%
105	AUTLAUTOLUS THERAPEUTICS PLC	422,167	$2.4M	0.05%
106	KNSAKINIKSA PHARMACEUTICALS LTD	130,000	$2.4M	0.05%
107	1T7TRICIDA INC	427,975	$2.3M	0.05%
108	GRCLGRACELL BIOTECHNOLOGIES INC	125,000	$1.9M	0.04%
109	ORTXUSDORCHARD THERAPEUTICS PLC	256,649	$1.9M	0.04%
110	CRDFCARDIFF ONCOLOGY INC	150,000	$1.4M	0.03%
111	ARNAEURARENA PHARMACEUTICALS INC	20,000	$1.4M	0.03%
112	ASNSUSDX4 PHARMACEUTICALS INC	103,980	$895K	0.02%
113	FATEFATE THERAPEUTICS INC	10,000	$824K	0.02%
114	IMV1EURIMV INC	234,374	$772K	0.02%
115	NERVGBPMINERVA NEUROSCIENCES INC	200,000	$584K	0.01%
116	—CEREVEL THERAPEUTICS HLDNG I	133,331	$563K	0.01%
117	—OUTLOOK THERAPEUTICS INC	416,666	$421K	0.01%
118	NKTREURNEKTAR THERAPEUTICS	20,000	$400K	0.01%
119	NUVB/WSNUVATION BIO INC	83,332	$222K	0.00%

PreviousPage 2 of 2